News of Note—Aurobindo recalls tainted valsartan APIs; Almac adds peptide capacity


> India’s Aurobindo, which earlier recalled 22 batches of its irbesartan API because it contained N-nitrosodiethylamine (NDEA), is now recalling 80 lots of amlodipine valsartan tablets USP, valsartan HCTZ tablets and valsartan tablets for the same reason. Release

> CDMO Almac Group has added a second line for high throughput GMP peptide manufacturing at its facility in Edinburgh, Scotland, to meet demand from drugmakers working on patient-specific, individualized cancer vaccines. Release

> Cambrex, which makes small molecule generic APIs, has completed its $252 million buyout of Avista Pharma Solutions, a four-facility contract development, manufacturing and testing organization. Release  


Striving for Zero in Quality & Manufacturing

Pharmaceutical and medical device manufacturers strive towards a culture of zero – zero hazards, zero defects, and zero waste. This on-demand webinar discusses the role that content management plays in pharmaceutical manufacturing to help companies reach the goal of zero in Quality and Manufacturing.

> Three former Hikma manufacturing plants in Eatontown, New Jersey, have been acquired by a developer and private investment group, which will sell the equipment and convert the buildings to another use. Release

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.